StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$28.04−0.55 (-1.92%)

Close on Nov 17, 2026Market cap $2.20BP/E –Yield –

Celldex Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Celldex Therapeutics's price to book ratio was 3.3× on Nov 11, 2026, against 3.0× a year earlier. Over the last 5 years it ranged from 1.6× to 7.6×, with a median of 3.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.3×+0.3
2025Dec 31, 20253.0×+0.9
2024Dec 31, 20242.1×−5.5
2023Dec 29, 20237.6×+1.5
2022Dec 30, 20226.1×+1.9
2021Dec 31, 20214.1×+1.1
2020Dec 31, 20203.0×+2.7
2019Dec 31, 20190.3×+0.1
2018Dec 31, 20180.3×−1.4
2017Dec 29, 20171.7×+0.1
2016Dec 30, 20161.7×−3.2
2015Dec 31, 20154.9×−2.0
2014Dec 31, 20146.8×−5.7
2013Dec 31, 201312.5×+8.0
2012Dec 31, 20124.5×+3.1
2011Dec 30, 20111.4×+0.3
2010Dec 31, 20101.1×–

More Celldex Therapeutics figures

See a number that looks wrong?